Processa Pharmaceuticals, Inc. (PCSA): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a pharmaceutical company navigates the complex world of drug development to improve cancer treatment? Processa Pharmaceuticals Inc. (PCSA), currently valued at a market cap of just $1.31 million, focuses on developing Next Generation Chemotherapy (NGC) drugs designed to enhance both the safety and efficacy of existing treatments. But with a 99.98% decrease in stock price over the past 10 years, can Processa's unique 'regulatory science' approach and pipeline of modified FDA-approved oncology drugs turn the tide and deliver much-needed therapies to patients?

Processa Pharmaceuticals, founded in 2011 and based in Hanover, Maryland, operates as a clinical-stage biopharmaceutical company. The company's mission centers around improving the survival rates and quality of life for patients facing high unmet medical needs by focusing on oncology research and regulatory science. Processa develops drugs that are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.

Processa's approach involves modifying already-approved drugs to improve their effectiveness and safety, rather than creating entirely new compounds. The company's pipeline includes treatments like PCS6422 for metastatic colorectal cancer and breast cancer, PCS499 for ulcerative necrobiosis lipoidica, and PCS12852 for gastroparesis. As of April 2025, the stock price is approximately $0.25 per share, with a 52-week range between $0.2201 and $3.10.

Processa Pharmaceuticals, Inc. (PCSA) History

Processa Pharmaceuticals, Inc. Founding Timeline

Year established

Processa Pharmaceuticals, Inc. was founded in 2017.

Original location

The company is headquartered in Hanover, Maryland.

Founding team members

The key members of the founding team include:

• Dr. David Young: Co-founder, President, and Chief Executive Officer
• Dr. John M. Holaday: Co-founder and Chief Scientific Officer

Initial capital/funding

Information regarding the specific initial capital or funding amounts when Processa Pharmaceuticals was founded in 2017 is not readily available in the provided search results. Financial details about the initial stages of private companies are often not publicly disclosed.

Processa Pharmaceuticals, Inc. Evolution Milestones

Processa Pharmaceuticals, Inc. Transformative Moments

• Focus on Oncology: A key transformative decision was focusing the pipeline on oncology, particularly on developing drugs to improve the efficacy and reduce the toxicity of existing cancer treatments. This strategic focus has guided their research and development efforts.
• Clinical Trial Design and Execution: Successfully navigating the complexities of clinical trials, particularly in areas with high unmet needs like advanced colorectal cancer, has been critical. The company's ability to secure FDA agreement on trial designs marks a significant milestone.
• Financial Strategies: Successfully securing funding through its IPO and subsequent financial activities has enabled Processa to advance its clinical programs.

To gain more insights into the company's financial standing, consider exploring: Breaking Down Processa Pharmaceuticals, Inc. (PCSA) Financial Health: Key Insights for Investors

Processa Pharmaceuticals, Inc. (PCSA) Ownership Structure

Processa Pharmaceuticals features a mix of institutional, insider, and retail ownership, influencing its strategic direction and corporate governance.

Processa Pharmaceuticals, Inc. Current Status

Processa Pharmaceuticals, Inc. is a publicly traded company, listed on the NASDAQ under the ticker symbol PCSA. This allows the company to raise capital through the issuance of stock, making it accessible to a wide range of investors.

Processa Pharmaceuticals, Inc. Ownership Breakdown

The ownership of Processa Pharmaceuticals is distributed among various types of shareholders. Here's a breakdown:

Processa Pharmaceuticals, Inc. Leadership

Processa Pharmaceuticals is guided by a team of experienced leaders. Key members include:

• David L. Nelson, Ph.D.: President, Chief Executive Officer, and Director.
• Michael Floyd, M.D.: Chief Medical Officer.
• Angela Bitting, J.D.: General Counsel and Corporate Secretary.

For more insights into the company's goals, check out Mission Statement, Vision, & Core Values of Processa Pharmaceuticals, Inc. (PCSA).

Processa Pharmaceuticals, Inc. (PCSA) Mission and Values

Processa Pharmaceuticals is dedicated to developing drugs that enhance the efficacy and reduce the toxicity of existing cancer treatments, aiming to improve the lives of patients. The company's values are centered around innovation, patient-centricity, and scientific rigor.

Processa Pharmaceuticals' Core Purpose

Official mission statement

Processa Pharmaceuticals' mission statement is to improve the survival and quality of life for cancer patients by developing novel therapies that work with and improve the effectiveness of current cancer treatments. This involves:

• Developing drugs designed to increase the efficacy and safety of existing cancer therapies.
• Focusing on unmet needs in cancer treatment.
• Advancing innovative scientific approaches to oncology.

Vision statement

Processa Pharmaceuticals envisions a future where cancer treatments are more effective, less toxic, and accessible to all patients in need. Key elements of their vision include:

• Becoming a leader in the development of next-generation cancer therapies.
• Creating significant value for patients, healthcare providers, and shareholders.
• Establishing strategic partnerships to expand the reach and impact of their drugs.

Company slogan/tagline

While Processa Pharmaceuticals doesn't have a widely publicized official slogan, their activities and communications reflect a commitment to 'Enhancing Cancer Therapy.' This is demonstrated through:

• Focusing on synergistic drug development.
• Prioritizing patient outcomes in their research and development efforts.
• Communicating a clear and consistent message about improving cancer treatment paradigms.

For more in-depth information, you can explore: Mission Statement, Vision, & Core Values of Processa Pharmaceuticals, Inc. (PCSA).

Processa Pharmaceuticals, Inc. (PCSA) How It Works

Processa Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company focused on developing next-generation chemotherapeutics to improve the efficacy and safety for patients suffering from cancer.

Processa Pharmaceuticals, Inc.'s Product/Service Portfolio

Processa Pharmaceuticals, Inc.'s Operational Framework

Processa Pharmaceuticals focuses on advancing its drug candidates through clinical trials, aiming to demonstrate improved efficacy and safety profiles compared to existing treatments. Their operational framework includes:

• Drug Development: Identifying and developing promising drug candidates based on existing chemotherapeutic agents.
• Clinical Trials: Conducting rigorous clinical trials to evaluate the safety and efficacy of their drug candidates.
• Regulatory Approval: Seeking regulatory approval from agencies such as the FDA to bring their products to market.
• Partnerships: Collaborating with research institutions and other companies to advance their development programs.

The company emphasizes a streamlined development process, concentrating on drugs that have already shown some efficacy but can be improved. As of the fiscal year 2024, Processa Pharmaceuticals reported a net loss of $17.1 million, or $2.31 per share, reflecting ongoing investment in research and development activities. The company’s research and development expenses totaled $8.9 million for the same period.

Processa Pharmaceuticals, Inc.'s Strategic Advantages

Processa Pharmaceuticals aims to leverage several strategic advantages to achieve market success:

• Next-Generation Technology: Developing innovative chemotherapeutics that can overcome the limitations of existing treatments.
• Experienced Team: A management team with experience in drug development and commercialization.
• Focus on Unmet Needs: Addressing the needs of cancer patients who have limited treatment options.
• Intellectual Property: Protecting their drug candidates with patents and other intellectual property rights.

The company's approach involves strategically improving existing drugs to enhance their effectiveness and reduce toxicity. This method potentially lowers development risks and costs compared to creating entirely new chemical entities. This information provides a clear picture of how Processa Pharmaceuticals operates and strives to create value in the biopharmaceutical industry. You might also be interested in Exploring Processa Pharmaceuticals, Inc. (PCSA) Investor Profile: Who’s Buying and Why?

Processa Pharmaceuticals, Inc. (PCSA) How It Makes Money

Processa Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company and currently does not generate revenue from product sales. Its primary focus is on developing and commercializing novel cancer therapeutics.

Processa Pharmaceuticals, Inc.'s Revenue Breakdown

As a clinical-stage biopharmaceutical company, Processa Pharmaceuticals currently has no products approved for sale. Therefore, it does not have revenue streams in the traditional sense. Its financial support comes from other sources.

Processa Pharmaceuticals, Inc.'s Business Economics

Processa Pharmaceuticals' business economics are characterized by substantial research and development expenses, typical of a clinical-stage biotech firm. Key aspects include:

• R&D Costs: A significant portion of its expenditure is dedicated to clinical trials, preclinical studies, and drug development efforts.
• Patents and Exclusivity: The company relies on securing and maintaining patents for its drug candidates to protect its intellectual property and ensure market exclusivity upon regulatory approval.
• Partnerships and Collaborations: Strategic alliances can help offset development costs and expedite the path to commercialization.
• Regulatory Milestones: Achieving key regulatory milestones, such as FDA approval, is critical for driving value and attracting further investment.

Processa Pharmaceuticals, Inc.'s Financial Performance

Processa Pharmaceuticals' financial performance reflects its status as a development-stage company. Key points include:

• Cash Position: As of December 31, 2023, Processa Pharmaceuticals reported total assets of $17.5 million, including cash and cash equivalents of approximately $13.8 million.
• Net Loss: For the year 2023, the company reported a net loss of approximately $17.8 million, or $2.49 per share.
• R&D Expenses: Research and development expenses totaled about $9.9 million for the same period.
• G&A Expenses: General and administrative expenses amounted to roughly $7.8 million.
• Financing Activities: The company depends on funding through equity offerings, debt, and potential grants to sustain its operations and advance its clinical programs.

For further insights into Processa Pharmaceuticals' financial health, you can explore this resource: Breaking Down Processa Pharmaceuticals, Inc. (PCSA) Financial Health: Key Insights for Investors

Processa Pharmaceuticals, Inc. (PCSA) Market Position & Future Outlook

Processa Pharmaceuticals is navigating a challenging market landscape, focusing on developing next generation chemotherapy to improve the efficacy and safety for cancer patients. Their future outlook hinges on successful clinical trials and strategic partnerships.

Competitive Landscape

Opportunities & Challenges

Industry Position

Processa Pharmaceuticals occupies a niche position within the pharmaceutical industry, concentrating on developing innovative cancer treatments. Key aspects of their industry standing include:

• Focus on Novel Therapies: Processa is dedicated to creating next-generation chemotherapies designed to be more effective and less toxic than current treatments.
• Strategic Development: The company strategically advances its drug candidates through clinical trials, aiming to address unmet needs in cancer care.
• Partnership Potential: While currently smaller in market share, Processa aims to enhance its position through strategic partnerships and successful drug development.

To gain more insights into the company's core principles, you can check: Mission Statement, Vision, & Core Values of Processa Pharmaceuticals, Inc. (PCSA).